CB Conversion Price Lowered, Dilution Risk Increased
에이프로젠바이오로직스
003060
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2719
Risk-adjusted indicator based on 2719 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Amended Conversion Price: 2,353 KRW/Share (Previously 3,778 KRW/Share)
- • Amended Convertible Shares: 21,589,460 Shares (Previously 13,446,267 Shares)
- • Dilution Rate: 149.80% of total shares (Previously 90.30%)
- • Total Convertible Shares (incl. existing): 46,016,552 Shares
- • Total Dilution Rate (incl. existing): 319.29% of total shares
AI Analysis Summary
Aprogen Biologics Inc. announced an amendment to its convertible bond issuance, significantly lowering the conversion price from 3,778 KRW to 2,353 KRW per share. This change increases the number of shares convertible from 13,446,267 to 21,589,460, raising the potential dilution rate from 90.30% to 149.80% of total shares. Including previously issued convertible bonds, the total potential dilution now stands at 319.29%. The funds are primarily for debt repayment, with 3.5B KRW to Aprochrom and 500M KRW to Aprogen I&C. This substantial increase in potential dilution is a negative development for existing shareholders.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.